NRx Pharmaceuticals, Inc. today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress disorder (PTSD).
NRx Pharmaceuticals, Inc. today announced that it has obtained approximately $11 million in unsecured debt financing (the “Note”) from Streeterville Capital, LLC, a Utah limited liability company.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced that they have agreed to a tentative settlement of their pending litigation. The parties have agreed to work collaboratively to finalize the settlement within the next 30 days.
NRx Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2022 and provided a business and clinical update.
NRx Pharmaceuticals, Inc. today announced that management will report second quarter 2022 financial results prior to the market open on August 15, 2022.
NRx Pharmaceuticals, Inc. announced today that the company’s Board of Directors appointed Seth Van Voorhees, Ph.D. as Chief Financial Officer and Treasurer effective June 13, 2022.
NRx Pharmaceuticals, Inc. today announced results of a review conducted by the Data Safety and Monitoring Board (DSMB) on May 25, 2022. The DSMB reviewed data of approximately 460 patients with Critical COVID-19 Respiratory Failure who were enrolled in the ACTIV-3b (TESICO) trial, most of which had reached the 90-day endpoint.
NRx Pharmaceuticals’ interim Chief Executive Officer, Robert Besthof, and other executive leaders presented a virtual update to the company’s business via webcast at the H.C. Wainwright & Co. Global Investment Conference on Tuesday, May 24, 2022.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2022 and provided a business and clinical update.
